Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10–15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodys-plastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducte...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Al-Kali, Aref, Quintás-Cardama, Alfonso, Luthra, Raja, Bueso-Ramos, Carlos, Pierce, Sherry, Kadia, Tapan, Borthakur, Gautam, Estrov, Zeev, Jabbour, Elias, Faderl, Stefan, Ravandi, Farhad, Cortes, Jorges, Tefferi, Ayalew, Kantarjian, Hagop, Garcia-Manero, Guillermo
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4089101/
https://ncbi.nlm.nih.gov/pubmed/23512829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23410
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items